Abstract
Fungi are some of the most neglected pathogens in terms of new drug discovery. Paracoccidioidomycosis, an endemic disease to South America, is caused by dimorphic fungi of Paracoccidioides genus. Reasonable citotoxicity, limited efficacy, and frequent use of current commercial antifungals have led to the emergence of resistance. Thus, the development of new antifungals with more selectivity and large spectrum of action is mandatory. In this work, six calix[n]arenes were synthesized and their activity explored against seven isolates of P. brasiliensis and P. lutzii. p-tert- Butylcalix[4]arene (CX1) was the most potent compound against fungal cells and exhibited the lowest toxicity on healthy mammalian cells (V79, hamster lung and MDCK, dog kidney). This is the first report on the effect of calix[n]arenes as growth inhibitors of Paracoccidioides fungi.
Keywords: Calix[n]arenes, P-tert-Butylcalix[n]arene, Antifungal, Paracoccidioides genus, Paracoccidioidomycosis, Dimorphic fungi, Mammalian cells, phenolic, anti-Paracoccidioides, Dimorphic fungus, pathogens, P. brasiliensis, P. lutzii
Letters in Drug Design & Discovery
Title: Synthesis and Anti-Paracoccidioides Activity of Calix[n]arenes
Volume: 9 Issue: 1
Author(s): Marcilene Coimbra de Oliveira, Fabiano Souza Reis, Angelo de Fatima, Thais Furtado Ferreira Magalhaes, Danielle Leticia da Silva, Raphael Rodrigues Porto, Giselle Almeida Watanabe, Cleide Viviane Buzanello Martins, Daniel Leite da Silva, Ana Lucia Tasca Gois Ruiz, Sergio Antonio Fernandes, Joao Ernesto de Carvalho and Maria Aparecida de Resende-Stoianoff
Affiliation:
Keywords: Calix[n]arenes, P-tert-Butylcalix[n]arene, Antifungal, Paracoccidioides genus, Paracoccidioidomycosis, Dimorphic fungi, Mammalian cells, phenolic, anti-Paracoccidioides, Dimorphic fungus, pathogens, P. brasiliensis, P. lutzii
Abstract: Fungi are some of the most neglected pathogens in terms of new drug discovery. Paracoccidioidomycosis, an endemic disease to South America, is caused by dimorphic fungi of Paracoccidioides genus. Reasonable citotoxicity, limited efficacy, and frequent use of current commercial antifungals have led to the emergence of resistance. Thus, the development of new antifungals with more selectivity and large spectrum of action is mandatory. In this work, six calix[n]arenes were synthesized and their activity explored against seven isolates of P. brasiliensis and P. lutzii. p-tert- Butylcalix[4]arene (CX1) was the most potent compound against fungal cells and exhibited the lowest toxicity on healthy mammalian cells (V79, hamster lung and MDCK, dog kidney). This is the first report on the effect of calix[n]arenes as growth inhibitors of Paracoccidioides fungi.
Export Options
About this article
Cite this article as:
Coimbra de Oliveira Marcilene, Souza Reis Fabiano, de Fatima Angelo, Furtado Ferreira Magalhaes Thais, Leticia da Silva Danielle, Rodrigues Porto Raphael, Almeida Watanabe Giselle, Viviane Buzanello Martins Cleide, Leite da Silva Daniel, Lucia Tasca Gois Ruiz Ana, Antonio Fernandes Sergio, Ernesto de Carvalho Joao and Aparecida de Resende-Stoianoff Maria, Synthesis and Anti-Paracoccidioides Activity of Calix[n]arenes, Letters in Drug Design & Discovery 2012; 9 (1) . https://dx.doi.org/10.2174/157018012798192991
DOI https://dx.doi.org/10.2174/157018012798192991 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis
Current Pharmaceutical Design Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development)
Current Pharmaceutical Design Editorial: Exciting Progresses in Stem Cell and Neural Stem Cell Research
Current Molecular Medicine Antipsychotics as Psychosis Drugs and Neuroprotective Promoters Evaluated by Chemical QSAR - in silico and in vivo Studies
Letters in Drug Design & Discovery Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Needle in a Haystack: Targeting Specific Glucuronidases Amid the Human Microbiome
Current Enzyme Inhibition Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Update on the Cardiac Safety of Moxifloxacin
Current Drug Safety Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry The Role of Immune and Inflammatory Mechanisms in ALS
Current Molecular Medicine Therapeutic Strategies in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)
Central Nervous System Agents in Medicinal Chemistry Bradykinin B1 Receptor Antagonists as Novel Analgesics: A Retrospective of Selected Medicinal Chemistry Developments
Current Topics in Medicinal Chemistry Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Current Pharmaceutical Design Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
CNS & Neurological Disorders - Drug Targets Mucoadhesive Vaginal Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation 2015 Update of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research to Clinical Management
Current Pharmaceutical Design Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways
Current Diabetes Reviews The Impact of Opioids on Cardiac Electrophysiology
Current Cardiology Reviews